13F reference period
Q2 2026
Security Snapshot
Bolt Biotherapeutics, Inc. - Common Stock, par value $0.00001 per share (BOLT) Institutional Ownership
CUSIP: 097702203
13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026
Institutions Reporting
23
Shares (Excl. Options)
596.53K
Full value: 596,527 · shares · 30 Jun 2026Price
$3.85
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- BOLT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 596,527
- Total 13F value
- $2,309,955
- Portfolio coverage rank
- 0%
- Share change
- -16,725
- Value change
- -$74,708
- Number of holders
- 23
- Shares outstanding
- 2,356,663
- SEC-reported price per share
- $3.68
- Insider filing price
- $3.68
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- BOLT - Bolt Biotherapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 097702203.
- 23 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 24 to 23 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.49M
Full value: $2,488,203 · USD · 31 Mar 2026.$2.31M
Full value: $2,309,955 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 23 institutions filings for Q2 2026.
Security key
097702203
13F reference period
Q2 2026
13F holders
23
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
BOLT full holder history
Bolt Biotherapeutics, Inc. SEC filings
Bolt Biotherapeutics, Inc. company facts
Bolt Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 097702203:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
BOLT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Coastlands Capital LP | 18% | $1,521,815 | 412,416 | Coastlands Capital LP | 30 Oct 2026 | |||
| RENAISSANCE TECHNOLOGIES LLC | 5.1% | $379,894 | 98,625 | Renaissance Technologies LLC | 24 Jun 2026 | |||
| Pivotal bioVenture Partners Fund I, L.P. | 4.6% | -30% | $478,373 | -$222,181 | 87,486 | -32% | Nan Fung Group Holdings Limited | 24 Feb 2026 |
| TANG CAPITAL MANAGEMENT LLC | 3.5% | -58% | $355,790 | -$531,990 | 66,879 | -60% | TANG CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
As of 30 Jun 2026,
23
institutional investors reported holding
shares of
Bolt Biotherapeutics, Inc. - Common Stock, par value $0.00001 per share (BOLT).
This represents
25%
of the company’s total
outstanding shares.
596.53K
Full value: 596,527 · shares · 30 Jun 20262.36M
Full value: 2,356,663 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
25%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 5.8% | 137,721 | 0% | 0.03% | $530,226 |
| RENAISSANCE TECHNOLOGIES LLC | 4.2% | 98,625 | +28% | 0% | $379,706 |
| Vivo Capital, LLC | 3.1% | 72,414 | 0% | 0.03% | $278,794 |
| CITADEL ADVISORS LLC | 2.4% | 56,903 | +463% | 0% | $219,077 |
| T3 Companies, LLC | 1.6% | 38,000 | 0% | 0.17% | $146,300 |
| Board of Trustees of The Leland Stanford Junior University | 1.5% | 35,977 | 0% | 0.03% | $138,511 |
| Pfizer Inc | 1.3% | 31,305 | 0% | 0.08% | $133,832 |
| Lynx1 Capital Management LP | 1.3% | 30,800 | 0% | 0.01% | $118,580 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 1.2% | 27,500 | 0% | 0.08% | $105,875 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.81% | 19,119 | -34% | 0% | $73,622 |
| Shay Capital LLC | 0.66% | 15,438 | +3.6% | 0.01% | $59,436 |
| BlackRock, Inc. | 0.41% | 9,711 | 0% | 0% | $37,388 |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.3% | 7,060 | 0% | 0% | $27,181 |
| Nan Fung Group Holdings Ltd | 0.21% | 5,000 | -83% | 0.01% | $19,250 |
| MORGAN STANLEY | 0.13% | 3,145 | -1.4% | 0% | $12,108 |
| VANGUARD FIDUCIARY TRUST CO | 0.13% | 3,095 | 0% | 0% | $11,916 |
| NewEdge Advisors, LLC | 0.11% | 2,530 | 0% | $9,740 | |
| Tower Research Capital LLC (TRC) | 0.07% | 1,710 | +56% | 0% | $6,584 |
| UBS Group AG | 0.01% | 255 | -68% | 0% | $982 |
| SBI Securities Co., Ltd. | 0.01% | 130 | +1200% | 0% | $501 |
| JPMORGAN CHASE & CO | 0% | 42 | 0% | 0% | $165 |
| CITIGROUP INC | 0% | 41 | 0% | $158 | |
| BARCLAYS PLC | 0% | 6 | 0% | 0% | $23 |
| Vanguard Global Advisers, LLC | 0% | 0 | -100% | $0 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0% | 0 | -100% | $0 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
6
Headline period
Q2 2026
Rows shown
1-6 of 6
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 53,807 | $198,023 | -$12,672 | $3.68 | 3 |
| 2026 Q2 | 596,527 | $2,309,955 | -$74,708 | $3.85 | 23 |
| 2026 Q1 | 613,252 | $2,488,203 | +$42,876 | $4.04 | 24 |
| 2025 Q4 | 602,538 | $3,295,047 | -$1,398,347 | $5.47 | 21 |
| 2025 Q3 | 804,036 | $4,277,487 | -$449,347 | $5.32 | 24 |
| 2025 Q2 | 887,525 | $5,096,477 | +$5,096,477 | $5.77 | 24 |